- Research article
- Open Access
- Open Peer Review
Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation
BMC Health Services Researchvolume 7, Article number: 138 (2007)
Nearly half of all patients in the Intensive Care Unit (ICU) receive red blood cell (pRBC) transfusions (TFs), despite their associated complications. Restrictive transfusion strategy (Hemoglobin [Hb] < 7 g/dL) has been shown to reduce TF exposure. We estimated the potential annual reduction in transfusion-attributable severe acute complications (TSACs) and costs across the US ICUs with the adoption of restrictive strategy.
A model, utilizing inputs from published studies, was constructed. Step 1 calculated potential number of patients appropriate for this strategy. In step 2, total number of pRBC units avoided with the restrictive trigger was extrapolated to the annual TFs in the US ICUs. Step 3 quantified excess acute complications and the number of pRBC units TF/1 TSAC in the TRICC trial. Step 4 transformed restrictive strategy-related avoidance of pRBC units to a reduction in TSACs, and step 5 quantified the associated cost savings.
Of the 4.4 million annual ICU admissions, 1,020,800 comprised the at-risk population. The total of 1,295,126 units of pRBC ($643/unit) could be saved with the restrictive strategy. Based on the data from the TRICC trial, dividing the 49 excess complications in the liberal group into the calculated excess of pRBCs transfused (1,624 units) yielded the rate of 33 pRBC units per one complication. Thus, dividing 1,295,126 units saved by 33 units/1 TSAC, the base-case analysis showed that 39,246 TSACs could potentially be avoided annually in the US ICUs, with the cost savings of $821,109,826.
This model demonstrates that a restrictive transfusion strategy in appropriate at risk ICU patients is dominant and could result in improved quality of care and cost savings. Given the potential savings of 40,000 TSACs and nearly $1 billion, it is incumbent upon the intensivist community to promote more ubiquitous adoption of a clinically appropriate restrictive transfusion strategy in the ICU.
Allogeneic blood transfusion remains a cornerstone of therapy in the Intensive Care Unit (ICU), with nearly 50% of all ICU patients in the US and abroad receiving packed red blood cells (pRBCs) during their ICU course [1, 2]. At the same time, a large body of evidence specific to the acutely ill hospitalized patients indicates that allogeneic blood is associated with an increased risk of infectious complications [3–5] and increased hospital length of stay . Among the critically ill in particular, exposure to blood has been associated with a substantially increased risk of nosocomial infection [7–12], multiorgan failure , and death .
In addition to infectious complications, there are concerns about transfusion-related immunomodulation and a shrinking blood supply. Because of these issues, efforts have focused on ways to minimize an individual's exposure to pRBCs while in the ICU. One such effort was the TRICC trial , which showed that lowering of the transfusion trigger from 10 g/dL (liberal transfusion strategy) to 7 g/dL (restrictive transfusion strategy) in appropriate ICU patients results in comparable, and possibly even somewhat better, outcomes, with a substantial reduction in blood exposure and utilization. Notably there was a significant reduction in certain acute complications in the restrictive when compared to the liberal transfusion strategy group.
Unfortunately, recent data have indicated that utilization of the lower trigger is quite variable [1, 2, 16], particularly among patients on mechanical ventilation . This indicates that we may be exposing the critically ill patients to potentially avoidable allogeneic blood, and may in turn be increasing their risk and overall number of transfusion-attributable severe acute complications (TSACs). Furthermore, since allogeneic blood carries an economic cost, there may be an opportunity to improve quality of ICU care while at the same time saving healthcare dollars via a restrictive transfusion strategy.
We sought to quantify the potential extent to which reducing the pre-transfision (pre-TF) hemoglobin (Hb) from the current practice levels to 7 g/dL, in appropriate patients, may result in the prevention of transfusion-attributable severe acute complications (TSACs). We additionally calculated the potential pRBC units and cost savings that may be realized with this reduction of overall utilization of blood. To address these questions, we constructed a simulation model based on recently published studies.
No human subjects were enrolled in the study, and, thus, the study was exempt from regulations guiding protection of human subjects. This is a secondary analysis based on previously published and peer-reviewed data. All calculations were performed in Microsoft Excel. Multivariate simulations and sensitivity analyses were performed using Crystal Ball® software (Decisioneering, Inc., Denver, CO).
We created an analytic model to determine the number of TSACs avoided annually in the US based on universal adoption of a restrictive transfusion strategy, defined as a transfusion trigger of < 7 g/dL . Additionally, we estimated the potential number of units of pRBCs saved and the direct cost savings that would result from this reduction in blood utilization. The model was built from the perspective of a hospital.
The model was designed to calculate the net difference in the frequency of TSACs in the US annually as a function of the decision to use lower (Hb < 7 g/dL) vs. current (Hb ~8.5 g/dL) transfusion trigger among patients determined to be at risk for a late transfusion (Figure 1). Late transfusions were defined as those required on and subsequent to ICU day #3 in the absence of active bleeding. We first determined the number of complications in a baseline scenario without the use of lower pre-TF Hb and then subtracted from that the number of complications in a situation where the trigger of < 7 g/dL was used uniformly. This equation (and other computations for this analysis) is illustrated in Table 1.
The number of TSACs annually in the US can be computed based on 1) the estimated US ICU adult population considered at risk for a late transfusion, 2) the average number of pRBCs given to these individuals, and 3) the risk for a TSAC as a function of the number of pRBC units transfused. Tables 2, 3, 4 show our estimates for these variables and their sources in the literature. We relied on a recent epidemiologic survey  to approximate the US ICU population and then assumed 80% of these subjects were adults . Since the TRICC trial utilized an artificially high TF trigger of 10 g/dL in the liberal arm, the data from this arm of the trial could not be used to estimate the extent of pRBC utilization in the current ICU practice environment. For this reason, transfusion practice and the amount of pRBCs given to an average ICU patient in the absence of a uniform utilization of a restrictive strategy was abstracted from the placebo arm of a recent randomized trial assessing the impact of recombinant human erythropoietin (rHuEPO) on transfusion utilization in critically ill subjects . In this trial there was no uniform transfusion protocol, and the mean pre-TF Hb was 8.57 g/dL .
To estimate the risk for TSACs we extracted additional data from the trial by Hebert et al. . In this study subjects were randomized to either a restrictive transfusion strategy or a liberal approach. We defined as a TSAC all serious cardiovascular complications and cases of ARDS. We selected these endpoints from that trial as TSAC for two reasons: 1) they were objectively defined and recorded and 2) they essentially were shown to occur at different rates in the liberal and restrictive cohorts. More specifically, there were 33 fewer cardiovascular complications and 16 fewer instances of ARDS among those randomized to the restrictive approach (Table 3). We assumed that any difference in TSACs in the Hebert et al. trial reflected the results of differential exposure to pRBCs, and that the relationship between pRBC administration and TSACs followed a linear dose-response relationship (i.e., increasing risks for TSAC increased with greater exposure to pRBCs [11, 12, 20]). Dividing the total difference in TSACs into the calculated aggregate total difference in units of pRBCs administered between the two arms indicates that for every 33 units of pRBCs avoided, one TSACs is prevented (Table 3).
To calculate the number of TSACs avoided with the reduction of the transfusion trigger to 7 g/dL, it was first necessary to assess how many units of pRBCs might potentially be avoided with the universal use of 7 g/dL as the pre-TF Hb (Table 4). To evaluate this required two inputs: the proportion of US adult ICU patients who might be at risk for late transfusions, and the risk reduction accompanying change to a restrictive transfusion strategy in the ICU. Because the literature is vague on the number of patients remaining in the ICU to constitute the "at risk" group for late transfusions, we used the percentage of the screened patients who were deemed eligible for enrollment from the Corwin study (29%). Next, we utilized the 3.01 units transfused/patient in the placebo group to calculate the overall blood utilization under current conditions in the patients at risk. Additionally, based on the experience of the TRICC investigators , we calculated that in the restrictive group the amount of transfused blood is on average 1.74 units across all the patients in the group. Multiplying this by the number of patients at risk yielded the total blood utilization under the circumstances of universal adoption of the restrictive transfusion practice. The difference between blood utilization under current conditions and that under universal use of restrictive practices was the potential number of pRBC units saved with the restrictive strategy institution (Table 4). As a final step, to calculate the potential number of TSACs avoided annually by using the Hb trigger of 7 g/dL, we simply divided the calculated number of units per 1 TSAC (n = 33) into the potential number of units saved with the restrictive strategy (Table 4).
Calculation of the cost savings associated with the reduced blood utilization was a simple product of the current cost of 1 unit of pRBC and the total number of units avoided. We determined the costs of a pRBC unit to be $634 from a report by Cremieux et al.  (year 2000 cost adjusted to 2005 US dollars based on the medical care services component for the Consumer Price Index).
Monte Carlo simulations and sensitivity analyses
Because of uncertainty surrounding the point estimates for various model inputs, we conducted several Monte Carlo simulations and sensitivity analyses to assess the stability of these observations (Table 5). Monte Carlo simulation is a technique that allows resampling from the same population while varying several inputs simultaneously, thus resulting in random multivariate sampling of input variables across their corresponding ranges. We varied three inputs across a range of plausible values: the proportion of all adult ICU patients annually at risk for a late transfusion, the number of pRBCs required to precipitate one TSAC, and the cost of a unit of pRBC. Each of the outcomes, total TSACs avoided, total number of pRBCs saved and the cost savings associated with saving the number of pRBC units, was tested in 10,000 simulation trials, while simultaneously and randomly varying the three input values. Sensitivity analyses were performed to assess which input variables accounted for the largest amount of variation in the predicted values of the outcome variables.
For the sensitivity analyses, the lower and upper bounds for the input variables were derived as follows:
The proportion of all adult ICU patients annually at risk for a late transfusion were obtained from the TRICC trial (15):
Lower bound = percent of the patients of the total pool screened who gave their consent to participate in the trial (13%)
Upper bound = percent of all patients screened who were deemed eligible for the study
For the number of pRBCs required to precipitate one TSAC, the upper and lower bounds were obtained using the 95% confidence interval associated with the reduction in the risk of these events due to the restrictive transfusion strategy as compared to the liberal transfusion strategy in the TRICC trial (15). Specifically, the absolute difference in TSACs between the liberal and restrictive groups was adjusted to fall from a lower bound of 3 to an upper bound of 87. Thus one TSAC is avoided for between 552 units (where the effect of adopting a restrictive strategy would be the smallest – least effective) to 19 units (where the effect of adopting a restrictive strategy would be the greatest – most effective) of pRBCs transfused.
Because the cost of a unit of blood varies from region to region and tends to vary according to the underlying disease state (21), the upper and lower bounds of cost of a unit of pRBC were based largely on anecdotal reports of the cost of blood. To be inclusive, the lower bound used was $250 and the upper $800.
In our base-case scenario, and based on the inputs and assumptions described in the Methods section, we estimate that there are 1,020,800 adult subjects in ICUs in the US annually who may be at risk for a late transfusion Table 2). Utilizing current transfusion practices, these subjects receive 3,073,360 pRBC units. With the universal institution of a restrictive practice, the TF burden is reduced by 42% to 1,778,234 u pRBCs, resulting in a net savings of 1,295,126 units of pRBCs. Based on our estimated rate of TSACs in this population, this extent of transfusion avoidance prevents 39,246 additional TSACs annually, or approximately 1 TSAC per every 26 patients at risk for a late TF. Total annual blood management costs under current practice conditions are calculated to be $1,948,509,929, all due to the costs of pRBCs. With the restrictive strategy, the estimated cost savings realized would be $821,109,699 annually.
The base case, lower bound and upper bound values for the input variables in the simulations are shown in Table 5. After 10,000 trials for each outcome, the median values (95% confidence intervals) for annualized TSACs avoided, pRBCs saved and attendant cost savings were 39,246 (2,360 to 43,696), 1,295,126 (753,705 to 2,040,700), and $821,109,699 ($348,827,493 to $1,310,093,076), respectively. The worst case scenario was also examined. In the least effective scenario, where TSACs are infrequent (552 units pRBC/1 TSAC) and the lowest percentage of patients is at risk for late transfusions (13%), the number of TSACs avoided would be 1,052 annually. Conversely, in the most effective scenario, where TSACs are frequent (19 units pRBC/1 TSAC) and the highest percentage of patients is at risk for late transfusion (50%), there is a potential to avoid 84,137 TSACs.
While it is self-evident that the estimate of the proportion of ICU patients at risk for late transfusion contributed to 100% of the variability in the estimate of the number of pRBC units saved, it accounted for 59% of the variability in the estimated dollars saved, with the uncertainty around the cost of 1 unit of blood responsible for the remaining 41% of the variability. As for the variability in the estimates of the TSACs avoided, the single major contributor to this, with the 90% share, was the uncertainty in the estimate of the number of pRBC units associated with 1 TSAC; the remaining 10% of this outcome's variability was due to the uncertainty in the proportion of ICU patients at risk for a late pRBC transfusion.
This model-based simulation quantifies the magnitude to which the established literature suggests that TSACs are a significant burden in critically ill patients. Furthermore, our results indicate that efforts to prevent these TSACs through transfusion avoidance can enhance outcomes. Universal adoption of restrictive transfusion strategy represents one potential tool for transfusion avoidance. Our model underscores that a restrictive strategy may be a cost-saving, and thus dominant, option in an anemia management program, in addition to helping reduce the risk for the complications following pRBC transfusion.
Prior efforts to explore the relationship between transfusion and its negative sequelae in the ICU have focused on two areas: nosocomial infection and acute lung injury. Multiple observational analyses, both retrospective and prospective, have demonstrated a relationship between exposure to pRBCs and nosocomial infection. Taylor and colleagues, for example, in a review of their Project Impact database demonstrated an independent correlation between pRBC transfusion and nosocomial infections . Addressing ventilator-associated pneumonia (VAP) specifically, Shorr et al. demonstrated a link between transfusion and this process , while Earley and co-workers confirmed a connection between transfusion and VAP in a cohort of trauma patients . Recently Taylor et al. prospectively substantiated the nexus between transfusion and hospital-acquired infections .
Additionally, adverse pulmonary outcomes following transfusion are now better understood. Transfusion-related acute lung injury (TRALI) has emerged as a serious and underappreciated consequence of transfusion. Although estimated to occur in 1 in 5,000 transfusions, the incidence is likely higher in critically ill subjects where the condition may be difficult to distinguish from either the progression of previously underlying lung injury or other forms of pulmonary edema. Suggesting the existence of deleterious pulmonary complications of pRBC transfusions, Gong et al. reported that transfusion independently increased the risk for developing ARDS by 50% (adjusted odds ratio: 1.52, 95% CI: 1.00–2.31) in ICU patients with predisposing factors for ARDS . Similarly, Kahn and colleagues in a group of individuals with subarachnoid hemorrhage noted that pRBC transfusion independently more than doubled the probability of ARDS . Most recently another cohort study of nearly 5,000 critically ill patients found an adjusted odds ratio of 2.80 (95% confidence interval 1.90–4.12) of developing ARDS in association with pRBC transfusions and a dose-response relationship . Finally, Gajic and coworkers have demonstrated an 18% absolute reduction in the development of acute lung injury in association with instituting a protocol limiting high tidal volume ventilation and inappropriate transfusions .
In light of these results, several systematic attempts have been made to limit the risks related to transfusion. Some advocate broader use of leukoreduction. Through leukoreduction, fewer pro-inflammatory mediators are infused into the recipient, and in turn, a less intense pro-inflammatory response arises. Despite theoretical benefits, it is unclear if leukoreduction will meaningfully decrease the rate of TSACs. In a large analysis of the Canadian experience with leukoreduction, post-transfusion fever was reduced, but there was no evident impact on nosocomial infection rates . A recent randomized trial in acute trauma patients also failed to show any advantages of leukoreduction .
Recent efforts to limit ICU patients' exposure to allogeneic blood prompted a number of treatment studies with the rHuEPO. Thus, a 1999 study by Corwin et al. demonstrated a nearly 50% reduction in blood utilization, as well as a trend toward increased transfusion independence in the rHuEPO group . A large Phase IIB follow-on trial by the same investigators found a 10% increase in transfusion avoidance and a 19% decrease in overall blood utilization . Unfortunately, likely due to sample size, neither trial demonstrated a reduction in adverse events that may be attributable to exposure to allogeneic blood, or a favorable difference in other important outcomes. A large Phase III study was recently completed and should shed some light on the outstanding questions of how rHuEPO may fit into the blood management scheme in the ICU .
Reliance on a restrictive transfusion strategy, on the other hand, has appeared more successful at altering outcomes. As noted earlier, Hebert and colleagues showed that lower levels of hemoglobin are well tolerated in most critically ill patients, and that in some subjects fewer transfusions may be associated with improved outcomes . Unfortunately, although some larger institutions appear to have successfully adopted a restrictive transfusion strategy , it is noteworthy that recent large European and US observational studies suggest that the transfusion trigger in most ICUs remains on average at approximately 8.5 g/dL (1, 2), and is actually even higher in the subgroup of patients on mechanical ventilation .
Why is it important to appreciate the extent of the burden of TSACs? An outcome has to be measured before it can be improved. This is most evident with blood stream infection  and ventilator-associated pneumonia [11, 20, 32], which have enjoyed improved outcomes through interventions aimed at their prevention [33, 34]. Our study, by estimating their clinical and economic burden, sets the stage for focusing similar efforts to quantify and prevent some of the avoidable TSACs. An immediate action that may improve these outcomes is to adhere to the restrictive transfusion strategy whenever clinically feasible.
Our project's purpose was to determine to what extent universal adoption of a restrictive transfusion strategy might enhance efforts at transfusion avoidance and with what potential direct cost savings to the system. In that vein, our results show that a restrictive strategy may result in a substantial benefit to the patient and the system through avoidance of TSACs. For instance, we calculated that across-the-board utilization of a restrictive trigger would result in direct blood cost savings of $821 million annually. Given that ICU-acquired complications have substantial humanistic and economic costs , this strategy is likely to be even more attractive when one examines it in the context of ICU outcomes as a whole.
One prior report has attempted to detail the burden of blood-related complications in the ICU patients . However, their calculations were based on estimates generated from epidemiologic data dealing with all subjects transfused, and not only those who are critically ill. As such, it is not clear that the results from reports dealing with populations of mixed severity of illness are generalizable to critically ill subjects. For example, TRALI arising in an otherwise mildly ill person is likely to have different consequences than TRALI in an already mechanically ventilated patient. Additionally, Shermock and co-workers only focused on several well-defined and rare transfusion-related complications . They addressed viral transmission, bacterial contamination, and other similar processes that most clinicians would a priori associate with de minimus risk. Although possessing clear diagnostic criteria, these complications are likely not the major concerns of the intensivist. Hence, we sought to build and to expand on their efforts by exploring recently defined complications of transfusion that have been specifically described in critically ill patients.
In addition to focusing on outcomes that arise in the ICU, our analysis has several other strengths. We relied on data from recent reports describing the results of transfusion in critically ill patients. Moreover, most of the outcome inputs used in our model represent results of randomized, controlled trials [15, 16]. Thus differences between those transfused and not transfused can be assumed to be directly attributable to added exposure to pRBCs. We also were conservative in our actual assumptions. Rather than assuming all subjects in an ICU might be at risk for a late transfusion, for example, we postulated that about 1/3 of all subjects might fit into this category. Furthermore, to formally evaluate the impact of uncertainty surrounding the point estimates for the model inputs, we conducted several sensitivity analyses to test the robustness of our conclusions. Finally, the model's transparency should aid in its applicability to concrete clinical situations.
Nonetheless, our study has several important limitations. First, despite our attempt to acknowledge and adjust for uncertainty, the data from which we draw our model inputs are limited. Unfortunately there are relatively few well-done studies exploring transfusion epidemiology, potential adverse events related to transfusion in the critically ill, and the significance of adoption of restrictive transfusion strategy in the ICU in the real world. Studies quantifying the actual cost of blood in the ICU setting are scarce as well. For this reason our final sensitivity estimates are relatively broad and imply intrinsic sensitivity to the accuracy of the input variables' values. That is, the most significant influence on the number of TSACs avoided in the least effective scenario is the assumption that it takes 552 units to precipitate 1 TSAC. While this number is based on the 95% confidence intervals reported by Hebert , it needs to be viewed in the context of observational studies that suggest a much greater incremental risk associated with exposure to each unit of pRBCs [8, 11, 12]. Second, we assumed that the incidence of our primary outcomes of interest, cardiovascular complications and ARDS/ALI, follows a linear dose-response relationship with pRBC exposure. Although some observational studies suggest this to be the case [11, 12, 22], to the best of our knowledge, no well-designed prospective study has been carried out to confirm this. In reality, both of these adverse outcomes might not be linearly related to pRBC transfusion amounts, but could alternatively follow a threshold effect. Third we did not add the economic or clinical cost of an actual TSAC into our model due to the paucity of such data in peer-reviewed literature. Fourth, the data on liberal transfusion-associated complications are derived from a single trial . This may be problematic in several ways: 1). Risk estimates from a trial may not reflect accurately the risks in real practice, and 2). Given a vast list of exclusion criteria and treating physician's discretion with respect to the decision to enroll patients, the results may not be generalizable to all ICU patients. Since a similar study is not likely to be replicated in subpopulations of patients of interest, we have attempted to overcome these short-comings by performing sensitivity analyses utilizing fairly conservative risk estimates and thus biasing the model against restrictive strategy. However, the possibility remains that by applying the strategy across the board, our model may thus overestimate the true effect that the institution of a sensible restrictive practice appropriate to a multitude of clinical situations would have. Finally, the sources for some of the critical inputs were derived from two different trials with potentially different populations. To assess this, we examined the potential differences between the restrictive strategy group in the TRICC trial and the placebo arm in the Corwin study (Table 6) [15, 16]. Although the placebo group in the Corwin trial (n = 652) was slightly larger than the restrictive arm in the TRICC study (n = 418), they were similar in their mean age, gender distribution and APACHE II scores. As for primary diagnoses, there was an imbalance between the groups in the proportion of patients with trauma, 20% vs. 48.5%, and cardiovascular disease, 18% vs. 5.4%, in TRICC and Corwin, respectively. While a deficit of cardiovascular diagnoses may have biased the Corwin placebo arm in the direction of a restrictive strategy, the excess of trauma patients would operate in the opposite direction, potentially biasing against a restrictive strategy. However, these limitation notwithstanding, to the best of our knowledge, ours is the first study to estimate the plausible range of avoidable costs and complications is restrictive transfusion strategy were to be adopted more uniformly in the ICUs across the US.
Our model estimates that universal adoption of a restrictive transfusion strategy could result in avoidance of nearly 40,000 transfusion-attributable severe acute complications annually among the critically ill in the US. This in turn could result in the savings of nearly $1 billion in costs associated with blood alone to the healthcare system. Furthermore, these findings remain robust across a range of sensitivity analyses. Efforts should be undertaken to support more ubiquitous adoption of a clinically appropriate restrictive transfusion strategy in the ICU.
intensive care unit
packed red blood cells
transfusion-attributable sever acute complication
acute respiratory distress syndrome
recombinant human erythropoietin
transfusion-related acute lung injury
acute lung injury
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study: Anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med. 2004, 32: 39-52. 10.1097/01.CCM.0000104112.34142.79.
Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellman A, Nollet G, Peres-Bota D: ABC (Anemia and Blood Transfusion in Critical Care) Investigators: Anemia and blood transfusion in critically ill patients. JAMA. 2002, 288: 1499-1507. 10.1001/jama.288.12.1499.
Carson JL, Altman DG, Duff A, Novek H, Weinstein MP, Sonenberg FA, Hudson JI, Provenzano G: Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999, 39: 694-700. 10.1046/j.1537-2995.1999.39070694.x.
Houbiers JG, van de Velde CJ, van de Watering LM, Hermans J, Schreuder S, Bijnen AB, Pahlplatz P, Schattenkerk ME, Wobbes T, de Vries JE, Klementschitsch P, van de Maas AH, Brand A: Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion. 1997, 37: 126-134. 10.1046/j.1537-2995.1997.37297203513.x.
Koval KJ, Rosenberg AD, Zuckerman JD, Aharonoff GB, Skovron ML, Bernstein RL, Su E, Chakka M: Does blood transfusion increase the risk of infection after hip fracture?. J Orthop Trauma. 1997, 11: 260-265. 10.1097/00005131-199705000-00004.
Vamvakas EC, Carven JH: Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection. Arch Pathol Lab Med. 1998, 122: 145-151.
Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS: Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002, 68: 566-572.
Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C: Impact of allogenic packed red blood cell transfusion on nosocomial infections rates in the critically ill patient. Crit Care Med. 2002, 30: 2249-2254. 10.1097/00003246-200210000-00012.
Dunne J, Malone DL, Tracy JK, Napolitano LM: Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt). 2004, 5: 395-404. 10.1089/sur.2004.5.395.
Malone DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM: Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma. 2003, 54: 898-905.
Shorr AF, Duh MS, Kelly KM, Kollef MH: Crit Study Group: Red blood cell transfusion and ventilator-associated pneumonia: A potential link?. Crit Care Med. 2004, 32: 666-674. 10.1097/01.CCM.0000114810.30477.C3.
Shorr AF, Jackson WL, Kelly KM, Fu M, Kollef MH: Transfusion practice and blood stream infections in critically ill patients. Chest. 2005, 127: 1722-1728. 10.1378/chest.127.5.1722.
Zallen G, Offner PJ, Moore EE, Blackwell J, Ciesla DJ, Gabriel J, Denny C, Silliman CC: Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg. 1999, 178: 570-572. 10.1016/S0002-9610(99)00239-1.
Purdy FR, Tweeddale MG, Merrick PM: Association of mortality with age of blood transfused in septic ICU patients. Can J Anaesth. 1997, 44: 1256-1261.
Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999, 340: 409-417. 10.1056/NEJM199902113400601.
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T: EPO Critical Care Trials Group: Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002, 288: 2827-2835. 10.1001/jama.288.22.2827.
Levy MM, Abraham E, Zilberberg M, MacIntyre NR: A descriptive evaluation of transfusion practices in patients receiving mechanical ventilation. Chest. 2005, 127: 928-935. 10.1378/chest.127.3.928.
Task Force on Values, Ethics and Rationing in Critical Care (VERICC). [http://www.VERICC.org]
Groeger JS, Guntupalli KK, Strosberg M, Halpern N, Raphaeli RC, Cerra F, Kaye W: Descriptive analysis of critical care units in the United States: patient characteristics and intensive care unit utilization. Crit Care Med. 1993, 21: 279-291. 10.1097/00003246-199302000-00022.
Earley AS, Gracias VH, Haut E, Sicoutris CP, Weibe DJ, Reilly PM, Schwab CW: Anemia management program reduces transfusion volumes, incidence of ventilator-associated pneumonia, and cost in trauma patients. J Trauma. 2006, 61: 1-7.
Cremieux PY, Barrett B, Anderson K, Slavin MB: Cost of outpatient blood transfusion in cancer patients. J Clin Onc. 2000, 18: 2755-2761.
Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K, Cappdoro C, Fu M, Plisko MS, Sadaka FG, Veremakis C: Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006, 34: 2302-2308. 10.1097/01.CCM.0000234034.51040.7F.
Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC: Clinical predictors of ARDS and mortality in ARDS: potential role of red cell transfusion. Crit Care Med. 2005, 33: 1191-1198. 10.1097/01.CCM.0000165566.82925.14.
Kahn JM, Caldwell EC, Deem S, Newell DW, Heckbert SR, Rubenfeld GD: Acute lung injury in patients with subarachnoid hemorrhage: incidence, risk factors, and outcome. Crit Care Med. 2006, 34: 196-202. 10.1097/01.CCM.0000194540.44020.8E.
Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF: Red blood cell transfusions and the risk of ARDS among critically ill: a cohort study. Crit Care. 2007, 11: R63-10.1186/cc5934.
Yilmaz M, Keegan MT, Iscimen R, Afessa B, Buck CF, Hubmayr RD, Gajic O: Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med. 2007, 35: 1660-1666. 10.1097/01.CCM.0000269037.66955.F0.
Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toy B, Schweitzer I, vanWalraven C, Devine D, Sher GD: Leukoreduction Study Investigators: Clinical outcomes following institution of the Canadian universal reduction program for red blood transfusions. JAMA. 2003, 289: 1941-1949. 10.1001/jama.289.15.1941.
Watkins TR, Rubenfeld GD, Martin TR: Effects of leukoreduced blood transfusion on acute lung injury in trauma patients: a randomized controlled trial [abstract]. Proc Am Thoracic Soc. 2006, 3: A301.
Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler D, Enny C, Colton T, Corwin MJ: Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double-blind placebo-controlled controlled trial. Crit Care Med. 1999, 27: 2346-2350. 10.1097/00003246-199911000-00004.
Hebert PC, Fergusson DA: Can erythropoietin eradicate red cell transfusions in critically ill?. Crit Care Med. 2006, 34: 2490-2491. 10.1097/01.CCM.0000235671.59923.CF.
Rana R, Afessa B, Keegan MT, Whalen FX Jr, Nuttall GA, Evenson LK, Peters SG, Winters JL, Hubmayr RD, Moore SB, Gajic O: Transfusion in the ICU Interest Group: Evidence-based red cell transfusion in the critically ill: Quality improvement using computerized physician order entry. Crit Care Med. 2006, 34: 1892-1897. 10.1097/01.CCM.0000220766.13623.FE.
Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH: VAP Outcomes Scientific Advisory Group: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002, 122: 2115-2121. 10.1378/chest.122.6.2115.
Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T: Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf. 2005, 31: 243-248.
Pronovost P, Needham D, Berenholtz S, Sinopli D, Csu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C: An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006, 355: 2725-2732. 10.1056/NEJMoa061115.
Shermock KM, Horn E, Lipsett PA, Pronovost PJ, Dorman T: Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med. 2005, 33: 497-503. 10.1097/01.CCM.0000155988.78188.EE.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/7/138/prepub
Dr. Shorr has served as a consultant to Ortho Biotech Clinical Affairs, LLC, manufacturer of epoetin alfa. Dr. Zilberberg is a former employee of and has served as a consultant to Ortho Biotech Clinical Affairs, LLC. She is also a stockholder in Johnson & Johnson, its parent company.
MDZ carried out study design, analysis, data interpretation, drafting the manuscript. AFS carried out study design, data interpretation, drafting the manuscript. Both authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.